Heart and mind: (2) Psychotropic and cardiovascular therapeutics

Postgraduate Medical Journal

Volumn 81, Issue 951, 2005, Pages 33-40

  Shah, Saeed Ullah ^a,b   Iqbal, Z ^a   White, A ^b   White, S ^b  

^a YSBYTY GWYNEDD   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMISULPRIDE; BUSPIRONE; CARDIOVASCULAR AGENT; CLOZAPINE; FLUPENTIXOL; GABAPENTIN; LAMOTRIGINE; LITHIUM; LOXAPINE; METHYLPHENIDATE; MIANSERIN; MIRTAZAPINE; PAROXETINE; PHENYTOIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRAZODONE; TRYPTOPHAN; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VIGABATRIN; VILOXAZINE; ZOPICLONE; ZOTEPINE;

AGITATION; AGRANULOCYTOSIS; ANOREXIA; ANXIETY DISORDER; BODY WEIGHT DISORDER; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; ECG ABNORMALITY; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; HYPOMANIA; INSOMNIA; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MANIA; MEDICAL PRACTICE; MENTAL DISEASE; MYOCARDITIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PANIC; PARANOIA; PRIAPISM; PRIMARY MEDICAL CARE; QT PROLONGATION; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SICK SINUS SYNDROME; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUDDEN DEATH; SUPRAVENTRICULAR PREMATURE BEAT; TACHYCARDIA; TORSADE DES POINTES; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 13244252556     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.015230     Document Type: Review

References (64)

1. Shah SU, White A, White S, et al. Heart and mind: (1) relationship between cardiovascular and psychiatric conditions. Postgrad Med J 2004;80:683-9.
2. Lopez AD, Murray O. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3.
3. Black DW, Fisher R. Mortality in DSM-III-R schizophrenia. Schizophr Res 1992;7:109-16.
4. Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders; do suicides and accidental deaths solely account for this excess? Arch Gen Psychiatry 1978;35:1181-5.
5. Reference withdrawn.
6. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-45.
7. Davies MJ. Unexplained death in fit young people. BMJ 1992;305:538-9.
8. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975;51:606-13.
9. Committee on Safety of Medicines. Drug-induced prolongation of the QT interval. Current Problems in Pharmacovigilance 1996;22:2.
10. Ban TA, St Jean A. Electrocardiographic changes induced by phenothiazine drugs. Am Heart J 1965;70:575-6.
11. Huston JR, Bell GE. The effects of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA 1966;198:16-20.
12. Alexander CS, Nino A. Cardiovascular complications in young patients taking psychotropic drugs. Am Heart J 1969;78:757-69.
13. Ayd FJ. Cardiovascular effects of phenothiazines. International Drug Therapy Newsletter 1970;V:1-8.
14. Lapierre YD, Lapointe L, Bordeleau JM, et al. Phenothiazine treatment and electrocardiographic abnormalities. Canadian Psychiatric Association Journal 1969;14:517-23.
15. Crane GE. Cardiac toxicity and psychotropic drugs. Diseases of the Nervous System 1970;31:534-9.
16. Raj MVJ, Benson R. Phenothiazines and the electrocardiogram. Postgrad Med J 1975;51:65-8.
17. Fowler NO, McCall D, Chou TC, et al. Electrocardiographic changes and cardiacarrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
18. Deglin SM, Deglin JM, Chung EK. Drug-induced cardiovascular diseases. Drugs 1977;14:29-40.
19. Wheatley D, ed. Stress and the heart. New York: Raven Press, 1981.
20. Swett CP, Shader RI. Cardiac side-effects and sudden death in hospitalized psychiatricpatients. Diseases of the Nervous System 1977;38:69-72.
21. Warner JP, Barnes TRE, Henry J. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996;93:311-13.
22. Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Clinical Toxicology 1995;33:199-204.
23. Jusic N, Lader M. Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 1994;165:787-91.
24. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug Reactions and Toxicology Review 1994;13:77-102.
25. Fulop G, Phillips RA, Shapiro AK, et al. EEG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-5.
26. Committee on Safety of Medicines. Cardiac arrhythmias with pimozide (Orap). Current Problems in Pharmacovigilance 1995;21:2.
27. Guillan RA, Yang C-P, Hocker EV. Antibody phenothiazines. Multiple antibody screening of patients under high doses. Journal of the Kansas Medical Society 1977;8:221-227.
28. Meeker JE, Herrmann PW, Som CW, et al. Clozapine tissue concentrations following an apparent suicidal overdose of clozaril. J Anal Toxicol 1992;16:54-6.
29. Jensen VE, Gotzsche O. Allergic myocarditis in clozapine treatment. Ugeskr Laeger 1994;156:4151-2.
30. Lilleng P, Morild I, Hope M. Clozapine and myocarditis. Tidsskr Nor Laegeforen 1995;115:3026-7.
31. Office of Population Censuses and Surveys. Mortality statistics, injury and poisoning England and Wales. Series DH4 No 18. London: HMSO, 1992.
32. Stoudemire A, Moran MF. Psychopharmacology in the medically ill patient. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1998:931-59.
33. Rossetti E, Fragasso G, Xuereb RG, et al. Antiischemic effects of intravenous diazepam in patients with coronary artery disease. J Cardiovasc Pharmacol 1994;24:55-8.
34. Stoudemire A, Moran MG, Fogel BS. Psychotropic drug use in the medically ill. Psychosomatics 1990;31:377-91.
35. Beliles K, Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 1998;39:S2-19.
36. Classman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993;269:2673-5.
37. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of enacinide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
38. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the anti arrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
39. Classman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54(suppl):16-22.
40. Neshkes RE, Gerner R, Jarvik LF, et al. Orthostatic effect of imipramine and doxepin in depressed geriatric outpatients. J Clin Psychopharmacol 1985;5:102-6.
41. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512-16.
42. Nelson JC, Kennedy IS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999;156:1024-8.
43. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:650-5.
44. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. I. J Clin Psychopharmacol 1996;16:273-85.
45. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychopharmacol 1995;56:574-9.
46. Stoudemire A, Moran MG, Fogel BS. Psychotropic drug use in the medically ill: II. Psychosomatics 1991;32:34-46.
47. Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes. Psychosomatics 1995;36:541-9.
48. Lieberman JA. Maximizing clozapine therapy: managing side-effects. J Clin Psychiatry 1998;59(suppl 3):38-43.
49. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
50. Stekler TL. Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hopsital. J Clin Psychopharmacol 1994;14:336-9.
51. Davis R, Peters DH, McTavish D. Valproate. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
52. Benassi E, Bo GP, Cociot L, et al. Carbamazepine and cordiac conduction disturbances. Ann Neurol 1999;22:280-1.
53. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988;49(suppl):58-61.
54. Van Amelsvoort T, Bakshi R, Devaux C, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-8.
55. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198-214.
56. McElroy SL, Keck PE. Antiepileptic drugs. In: Schwartzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:351-75.
57. Goa KL, Sorkin EM. Gabapentin. Drugs 1993;46:409-27.
58. Fitton A, Goa K. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
59. Gengo FM, Gabos C. Central nervous systems considerations in the use of beta-blockers, angiotension-converting enzyme inhibitors and thiazide diuretics in managing essential hypertension. Am J Cardiol 1988;116:305-10.
60. Thiessen BQ, Wallace SM, Blackburn JL. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990;150:2286-90.
61. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116:515-22.
62. Schleifer SJ, Slater WR, Macari-Hinson MM, et al. Digitalis and beta-blocking agents: effects on depression following myocardial infarction. Am Heart J 1991;121:1397-402.
63. Eisendrath SJ, Sweeney MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987;144:506-7.
64. Levenson JL. Cardiovascular disease. In: Stoudemire A, Fogel BS, eds. Psychiatric care of the medical patient. New York: Oxford University Press, 1993:539-63.